Gilead Sciences (GILD) on Watch After Merck (MRK) Prices Hep C Combo

Gilead Sciences (NASDAQ: GILD) shares were on watch Friday after Merck (NYSE: MRK) priced its newly approved Hepatitis C combo ZEPATIER (elbasvir and grazoprevir) at $54,600 for a 12-week regimen.

"After considering these factors, Merck has established a list price of $54,600 for a 12-week regimen, which the company believes to be in the range of net prices for other commonly used HCV direct-acting antiviral regimens at 12 weeks of therapy. Merck anticipates that this price, as well as our comprehensive access strategy to seek broad coverage across commercial and public segments, will help broaden and accelerate patient access to treatment and move us closer to our shared goal of reducing the burden of chronic HCV in the U.S," said Merck.

You May Also Be Interested In

• IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
• Tesla (TSLA) soars on Q1 print
• AGBA Group Holding (AGBA) selling off into close, down over 17%